Levodopa/carbidopa intraduodenal - AbbVie

Drug Profile

Levodopa/carbidopa intraduodenal - AbbVie

Alternative Names: ABT-SLV187; Carbidopa/levodopa enteral suspension; Carbidopa/levodopa intraduodenal; Duodopa; Duopa; LCIG; Levodopa/carbidopa intestinal gel

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeoPharma
  • Developer AbbVie
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 01 Sep 2017 Chemical structure information added
  • 28 Aug 2017 AbbVie terminates the phase III DYSCOVER trial in Parkinson's disease (Late-stage disease) in USA (NCT02799381)
  • 01 Dec 2016 AbbVie initiates enrolment in the DYSCOVER trial for Parkinson's disease (Late-stage disease) in USA, Spain, Italy, Greece and Slovakia (Intraduodenal) (NCT02799381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top